TAPIMMUNE announced that Dr. Wilson has been appointed President after Dr.John Bonfiglio’s resigned as Chief Operating Officer, President and director of TapImmune Inc. to pursue other opportunities.
Speaking for the Board of Directors, Chairman and CEO of TapImmune Dr. Glynn Wilson said that they have been fortunate to have John serve the Company initially as a consultant and subsequently as an officer and director. During John’s tenure as part of their management team, the Company successfully optimized and scaled up GMP manufacturing operations, allowing them to enter multiple Phase 2 clinical studies and to be listed on Nasdaq Capital Markets. As the company transitions into a focus on later stages of clinical development, He want to thank John and wish him the best in his future endeavours.